High-doses of antifolates, such as MTX, aminopterin, or pralatrexate, act by competitively inhibiting the binding of dihydrofolate reductase (DHFR) to folate, and disrupting de novo synthesis of DNA and RNA, thereby retarding the proliferation of cancer cells [18]. Here, DHFR is linked to cancer.